<p>biote Corp. (NASDAQ:BTMD - 获取免费报告) 的股价在周四的午盘交易中下跌了 0.9%。该公司的股价最低曾达到$2.18，最后交易价为$2.22。午盘交易中大约交易了 141,384 股，较平均每日交易量 296,497 股下降了 52%。该股票之前的收盘价为$2.24。</p>
<h2>分析师评级调整</h2>
<p>BTMD 成为多份研究分析师报告的主题。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 biote 的 “卖出（d+）” 评级。Truist Financial 在 4 月 16 日的研究报告中将 biote 的目标价从$5.00 下调至$4.00，并对该股票给予 “买入” 评级。B. Riley Financial 在 3 月 12 日的研究报告中将 biote 的目标价从$3.00 下调至$2.00，并对该股票给予 “中性” 评级。National Bank Financial 在 3 月 12 日的研究报告中设定了 biote 的目标价为$2.50。最后，TD Cowen 在 3 月 12 日的研究报告中将 biote 的目标价从$3.00 下调至$2.50，并对该股票给予 “买入” 评级。目前有两位投资分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为$2.75。</p>
<p><strong>查看我们最新的 biote 研究报告</strong></p>
<h2>biote 股票表现</h2>
<p>该公司的 50 日简单移动平均线为$1.79，200 日简单移动平均线为$2.31。该公司的市值为 8780 万美元，市盈率为 2.96，贝塔值为 1.29。</p>
<p>biote (NASDAQ:BTMD - 获取免费报告) 最近在 3 月 11 日发布了季度财报。该公司报告每股收益（EPS）为$0.06，超出市场共识预期的$0.05，超出幅度为$0.01。biote 的股本回报率为负的 23.41%，净利润率为 14.07%。该公司季度收入为 4641 万美元，而市场共识预期为 4579 万美元。整体来看，研究分析师预计 biote Corp.在当前财年将发布 0.32 的每股收益。</p>
<h2>机构投资者对 biote 的看法</h2>
<p>几家对冲基金和其他机构投资者最近买卖了该公司的股票。Rothschild Wealth LLC 在第四季度新购入了约 38 万美元的 biote 股份。Rice Hall James &amp; Associates LLC 在第三季度将其在 biote 的持仓增加了 86.6%。Rice Hall James &amp; Associates LLC 目前拥有 227,024 股该公司的股票，价值 68.1 万美元，此前在上个季度增持了 105,369 股。WINTON GROUP Ltd 在第三季度新购入了约 30.9 万美元的 biote 股份。State Street Corp 在第四季度将其在 biote 的持仓增加了 17.3%。State Street Corp 目前拥有 600,114 股该公司的股票，价值 156 万美元，此前在此期间增持了 88,402 股。最后，Bridgeway Capital Management LLC 在第二季度将其在 biote 的持仓增加了 142.1%。Bridgeway Capital Management LLC 目前拥有 121,053 股该公司的股票，价值 48.7 万美元，此前在此期间增持了 71,053 股。目前 21.68% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>biote 公司简介</h2>
<p>(获取免费报告)</p>
<p>biote Corp.在激素优化领域内运营实践建设业务。它培训医生和护士从业人员使用生物相似激素替代颗粒疗法来优化男性和女性的激素水平。该公司提供 Biote Method，这是一个全面的实践建设平台，为 Biote 认证的从业人员提供在激素优化领域开发的组件，包括 Biote Method 教育、培训和认证服务；实践管理软件，允许 Biote 认证的从业人员订购、跟踪和管理激素优化产品库存及其他行政要求；库存管理软件以监控颗粒库存；以及有关可用激素替代疗法产品的信息，以及数字和临床营销支持。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 biote</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 biote 吗？</h2>
<p>在你考虑投资 biote 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 biote 并不在名单上。</p>
<p>虽然 biote 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

BTMD

<p>biote Corp.（纳斯达克代码：BTMD）股价在午盘交易中下跌 0.9%，至 2.22 美元，成交量较平均水平下降 52%。分析师的评级意见不一，Weiss Ratings 给予 “卖出” 评级，而 Truist Financial 则给予 “买入” 评级，目标价为 4.00 美元。该股票的共识评级为 “持有”，目标价为 2.75 美元。公司报告上个季度收入为 4641 万美元，每股收益为 0.06 美元，均超过预期。机构投资者持有该股票的 21.68%，反映出对激素优化市场日益增长的兴趣</p>

<p>biote Corp. (NASDAQ:BTMD - Get Free Report)'s stock price dropped 0.9% during mid-day trading on Thursday . The company traded as low as $2.18 and last traded at $2.22. Approximately 141,384 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 296,497 shares. The stock had previously closed at $2.24.</p>
<div class="lb-trans"><p>biote Corp. (NASDAQ:BTMD - 获取免费报告) 的股价在周四的午盘交易中下跌了 0.9%。该公司的股价最低曾达到$2.18，最后交易价为$2.22。午盘交易中大约交易了 141,384 股，较平均每日交易量 296,497 股下降了 52%。该股票之前的收盘价为$2.24。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>BTMD has been the topic of a number of research analyst reports. Weiss Ratings reissued a &#34;sell (d+)&#34; rating on shares of biote in a research note on Monday, December 29th. Truist Financial reduced their price objective on biote from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, April 16th. B. Riley Financial reduced their price objective on biote from $3.00 to $2.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, March 12th. National Bank Financial set a $2.50 price objective on biote in a research note on Thursday, March 12th. Finally, TD Cowen reduced their price objective on biote from $3.00 to $2.50 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $2.75.</p>
<div class="lb-trans"><p>BTMD 成为多份研究分析师报告的主题。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 biote 的 “卖出（d+）” 评级。Truist Financial 在 4 月 16 日的研究报告中将 biote 的目标价从$5.00 下调至$4.00，并对该股票给予 “买入” 评级。B. Riley Financial 在 3 月 12 日的研究报告中将 biote 的目标价从$3.00 下调至$2.00，并对该股票给予 “中性” 评级。National Bank Financial 在 3 月 12 日的研究报告中设定了 biote 的目标价为$2.50。最后，TD Cowen 在 3 月 12 日的研究报告中将 biote 的目标价从$3.00 下调至$2.50，并对该股票给予 “买入” 评级。目前有两位投资分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为$2.75。</p>
</div><p><strong>View Our Latest Research Report on biote</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 biote 研究报告</strong></p>
</div><h2>biote Stock Performance</h2>
<div class="lb-trans"><h2>biote 股票表现</h2>
</div><p>The firm has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $2.31. The company has a market capitalization of $87.80 million, a PE ratio of 2.96 and a beta of 1.29.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为$1.79，200 日简单移动平均线为$2.31。该公司的市值为 8780 万美元，市盈率为 2.96，贝塔值为 1.29。</p>
</div><p>biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. biote had a negative return on equity of 23.41% and a net margin of 14.07%.The company had revenue of $46.41 million for the quarter, compared to the consensus estimate of $45.79 million. As a group, research analysts anticipate that biote Corp. will post 0.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>biote (NASDAQ:BTMD - 获取免费报告) 最近在 3 月 11 日发布了季度财报。该公司报告每股收益（EPS）为$0.06，超出市场共识预期的$0.05，超出幅度为$0.01。biote 的股本回报率为负的 23.41%，净利润率为 14.07%。该公司季度收入为 4641 万美元，而市场共识预期为 4579 万美元。整体来看，研究分析师预计 biote Corp.在当前财年将发布 0.32 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On biote</h2>
<div class="lb-trans"><h2>机构投资者对 biote 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rothschild Wealth LLC acquired a new position in shares of biote in the 4th quarter worth approximately $380,000. Rice Hall James &amp; Associates LLC grew its position in shares of biote by 86.6% in the 3rd quarter. Rice Hall James &amp; Associates LLC now owns 227,024 shares of the company's stock worth $681,000 after acquiring an additional 105,369 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of biote in the 3rd quarter worth approximately $309,000. State Street Corp boosted its position in biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company's stock valued at $1,560,000 after purchasing an additional 88,402 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company's stock valued at $487,000 after purchasing an additional 71,053 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了该公司的股票。Rothschild Wealth LLC 在第四季度新购入了约 38 万美元的 biote 股份。Rice Hall James &amp; Associates LLC 在第三季度将其在 biote 的持仓增加了 86.6%。Rice Hall James &amp; Associates LLC 目前拥有 227,024 股该公司的股票，价值 68.1 万美元，此前在上个季度增持了 105,369 股。WINTON GROUP Ltd 在第三季度新购入了约 30.9 万美元的 biote 股份。State Street Corp 在第四季度将其在 biote 的持仓增加了 17.3%。State Street Corp 目前拥有 600,114 股该公司的股票，价值 156 万美元，此前在此期间增持了 88,402 股。最后，Bridgeway Capital Management LLC 在第二季度将其在 biote 的持仓增加了 142.1%。Bridgeway Capital Management LLC 目前拥有 121,053 股该公司的股票，价值 48.7 万美元，此前在此期间增持了 71,053 股。目前 21.68% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>biote Company Profile</h2>
<div class="lb-trans"><h2>biote 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.</p>
<div class="lb-trans"><p>biote Corp.在激素优化领域内运营实践建设业务。它培训医生和护士从业人员使用生物相似激素替代颗粒疗法来优化男性和女性的激素水平。该公司提供 Biote Method，这是一个全面的实践建设平台，为 Biote 认证的从业人员提供在激素优化领域开发的组件，包括 Biote Method 教育、培训和认证服务；实践管理软件，允许 Biote 认证的从业人员订购、跟踪和管理激素优化产品库存及其他行政要求；库存管理软件以监控颗粒库存；以及有关可用激素替代疗法产品的信息，以及数字和临床营销支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than biote</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 biote</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in biote Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 biote 吗？</h2>
</div><p>Before you consider biote, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 biote 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 biote 并不在名单上。</p>
</div><p>While biote currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 biote 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

biote (NASDAQ:BTMD) Trading Down 0.9%  - What's Next?

Market Beat

biote Corp.

Truist Financial

Toronto Dominion Bank

道富银行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

State Street® US Equity Premium Inc ETF

biote（纳斯达克股票代码：BTMD）股价下跌 0.9% - 接下来会如何发展？